Having a second look at Antares Pharma, Inc. (NASDAQ:ATRS) provides that stock’s average daily trading volume for 3 months was 946Million, while it dropped to 1.43 Million when we calculate an average volume for past 10 days. ATRS has been the topic of several other research reports. Every day the website publishes the latest news of the business, technologies, politics, economy, culture, sports and the most interesting events in the world. Other research analysts have also recently issued research reports about the stock. ... About Antares Pharma. The average estimate is representing an increase of 5.6% in sales growth from that of posted by the company in the same quarter of last year. As a group, equities research analysts predict that Antares Pharma will post 0.06 EPS for the current year. Antares Pharma, Inc. is not obligated to update the press releases and information contained in this section of the Company’s website. Click here now. Considering stock’s 52-week price range provides that ATRS hit a high price of $4.9 and saw its price falling to a low level of $1.6 during that period. Antares Pharma (NASDAQ:ATRS) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, BidAskClub reports. your password Zacks Investment Research lowered Antares Pharma from a strong-buy rating to a hold rating in a research report on […] Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have received an average recommendation of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. $3.9900. A final reason to buy is the price. Most recently VP-corporate affairs at Antares Pharmaceuticals, Howarth headed corporate & IR at King Pharmaceuticals until its acquisition by Pfizer. Antares stock recently plunged 33% on less-than-unequivocally-good results for BioSante Pharmaceuticals' (Nasdaq: BPAX) LibiGel, for … Antares Pharma has a 52-week low of $1.60 and a 52-week high of $4.87. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $145.6 Million in 2020, which will be +17.5% more from revenue generated by the company last year. Log into your account. Antares Pharma story: Acquisition by Scott Longval of 16299 shares of IntriCon subject to Rule 16b 3 and other headlines for Antares Pharma Telos Corporation (TLS) Volatility Hits 600% – Here’s What A Good Investor Should Do, BioNTech SE (BNTX) Touches $105.78: At This Price, The Risk Is Worth It, National Oilwell Varco, Inc. (NYSE:NOV) Stock Forecast: Potential to Pass $17.5 in A Year, Analysts think Park Hotels & Resorts Inc. (NYSE:PK) could rise 32.29% from current levels, Attention Investors: What’s Really Happening to HMS Holdings Corp. (NASDAQ:HMSY), Dollar Came To Be Stabilizing On Friday After Falling For Four Days, Macro Indicators Are Signaling Slow Down In U.S. Economic Recovery. The firm had revenue of $40.00 million for the quarter, compared to analyst estimates of $36.09 million. Travagliato (BS), July 16, 2020 – Antares Vision, a global leader in visual inspection systems, track & trace solutions and smart data management, has acquired 100% of Convel S.r.l. Antares Pharma, Inc. (ATRS) is trading 81.88% from its 52 week low and -43.27% from its 52 week high. $0.0800. Convel specializes in inspection equipment providing leak detection for pharmaceutical products packaged in glass and plastic containers. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company. Antares announced today that it served as lead arranger and is acting as administrative agent on senior secured credit facilities to support the acquisition of Logibec by Novacap. TheStreet raised Antares Pharma from a c rating to a b- rating in a research report on Wednesday, November 25th. 10 Nov 2020 The firm has a market cap of $645.02 million, a PE ratio of 64.51 and a beta of 1.41. It further provides that stock’s current price level is 21.84% away from its 20-day simple moving average and is 27.45% off its SMA50. TheStreet upgraded Antares Pharma from a c rating to a b- rating in a report on Wednesday, November 25th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.01. ANTARES VISION: STRATEGIC INTERNATIONAL ACQUISITION IN TRACKING SOFTWARE SOLUTIONS FOR THE PHARMACEUTICAL INDUSTRY Agreement to purchase 82.83% of Tradeticity d.o.o. Institutional investors and hedge funds own 38.96% of the company’s stock. There is a secret stock that is LOADED with opportunity for savvy investors to make a fortune! BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. The average 12 month target price among brokerages that […] My price target thinking was explained in an August 17, 2017 report in which I … Figure 1 gives an overview of key transactions with generic drug companies in the last few years; as can be seen, transaction multiples have decreased and narrowed. In November the standing of shares short declined as it was 4.05 Million in the previous month. In comparing Antares Pharma, Inc. (ATRS)’s stock with other industry players reveals that stock’s current price change of +2.05% and that of -17.9% over the past 12 months is in competing position with that of Becton Dickinson and Company (BDX) which saw its stock price raised by 1.39% in the last trading and went through a decline of -6.92% in past 12-month trading. These estimates are suggesting current year growth of -7% for EPS and 3.17% growth next year. Antares Pharma, Inc. has a P/E ratio of 120.91 against that of Becton Dickinson and Company’s 91.13 while Align Technology is showing 23.96 for the same. Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 7.49% while it is 43.6% for the institutional holders. Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. Other research analysts have also issued research reports about the company. Previously, Mr. Greenleaf served as Chairman and CEO of Sucampo Pharmaceuticals and led the Company’s acquisition by Mallincrodt Pharmaceuticals for $1.2 billion. Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report report published on Thursday morning, BidAskClub reports. Zacks Investment Research lowered Antares Pharma from a strong-buy rating to a hold rating in a research report on Monday, October 12th. ATRS. Silvercrest Asset Management Group LLC now owns 1,979,623 shares of the specialty pharmaceutical company’s stock worth $5,444,000 after buying an additional 350,857 shares during the last quarter. Number of outstanding shares of the stock stood at 166.67 Million. Our Patient Commitment. Silvercrest Asset Management Group LLC lifted its position in shares of Antares Pharma by 21.5% during the 2nd quarter. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Beta is valued at 1.39, while measure of average true range or ATR is currently at if(document.body.clientWidth>1500){document.write(”)}else{document.write(”)}. your username. In contrast, when we review ATRS stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. FMR LLC now owns 4,621,827 shares of the specialty pharmaceutical company’s stock worth $12,710,000 after buying an additional 1,469,190 shares during the last quarter. They suggested that in the process company could generate revenue of as low as $35.1 Million which could climb up to $44.5 Million to hit a high. On November 19, 2019, Antares Pharma, Inc. acquired life science company Idorsia Pharmaceuticals Ltd. This shows up a 2.37% of Short Interest in company’s outstanding shares on the day. Antares Pharma, Inc. (NASDAQ:ATRS) concluded the trading at $3.99 on Thursday, Dec 17 with a rise of 2.05% from its closing price on previous day. 17-Jul-2020 . We do not sell or share your information with anyone. Industry’s another major player Align Technology (ALGN) has jumped 2.01% up in previous session, but over the past year has faced a rise of 93.21%, while Mckesson Corp (MCK) was also up 2.05% however its price remained floating in the red at -17.9% over the same period. Get the hottest stocks to trade every day before the market opens 100% free. The shares were acquired at an average cost of $2.85 per share, with a total value of $46,740.00. Oracle Investment Management Inc. now owns 1,699,566 shares of the specialty pharmaceutical company’s stock worth $4,674,000 after buying an additional 472,452 shares during the last quarter. Pfizer is the best candidate to buy … Helmerich & Payne (NYSE:HP) Rating Lowered to Neutral at JPMorgan Chase & Co. Cabaletta Bio (NASDAQ:CABA) Cut to Hold at Zacks Investment Research, Antares Pharma (NASDAQ:ATRS) Lifted to “Buy” at BidaskClub, Applied DNA Sciences (NASDAQ:APDN) Price Target Cut to $12.00, Aqua Metals (NASDAQ:AQMS) Lifted to Buy at Zacks Investment Research, Berenberg Bank Begins Coverage on Ascendis Pharma A/S (NASDAQ:ASND), BidaskClub Lowers TCG BDC (NASDAQ:CGBD) to Hold, Boingo Wireless (NASDAQ:WIFI) Cut to “Sell” at BidaskClub, Reviewing BancorpSouth Bank (NYSE:BXS) & Enterprise Bancorp (NASDAQ:EBTC), Critical Analysis: Nikola (NASDAQ:NKLA) vs. Greenkraft (OTCMKTS:GKIT), -$0.16 Earnings Per Share Expected for BigCommerce Holdings, Inc. (NASDAQ:BIGC) This Quarter, Inphi Co. (NASDAQ:IPHI) Receives $171.00 Average PT from Brokerages, Ambarella (NASDAQ:AMBA) Given New $75.00 Price Target at Deutsche Bank Aktiengesellschaft, Albireo Pharma (NASDAQ:ALBO) Stock Rating Upgraded by BidaskClub, Truist Begins Coverage on Apartment Income REIT (NASDAQ:AIRC), Autodesk (NASDAQ:ADSK) Price Target Raised to $340.00, RADA Electronic Industries (NASDAQ:RADA) Shares Gap Up to $8.75, Mereo BioPharma Group (NASDAQ:MREO) Shares Gap Up to $2.21, MarketBeat.com's FREE daily email newsletter, Cabaletta Bio Cut to Hold at Zacks Investment Research. Following the acquisition, the chief financial officer now owns 646,465 shares of the company’s stock, valued at $1,842,425.25. Analysts are in estimates of $0.03 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $0.06 for 2020 with estimates of that growing to $0.25 in next year. Company’s P/E ratio for the trailing 12 months is 120.91. Antares Pharma, Inc. (ATRS) has a 52 week range of $1.6000 to $5.1300. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. The Company’s most targeted sectors include life science (100%). According to ratings assigned by 6 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending Antares Pharma, Inc. (ATRS) as a Hold, while 6 are in view that stock is a Buy. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. Long term indicators are suggesting an average of 100% Buy for it. Vanguard Group Inc. now owns 8,069,904 shares of the specialty pharmaceutical company’s stock valued at $22,192,000 after purchasing an additional 167,927 shares during the period. Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and … ATRS has been the topic of several other research reports. Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $39.97 Million. Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. In other Antares Pharma news, CFO Fred M. Powell bought 16,400 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. He held top jobs at … Helmerich & Payne Rating Lowered to Neutral at JPMorgan Chase & Co. Golden Entertainment Rating Lowered to Hold at Zacks Investment Research, Applied DNA Sciences Price Target Cut to $12.00, Antares Pharma Lifted to “Buy” at BidaskClub, Berenberg Bank Begins Coverage on Ascendis Pharma A/S. And five have assigned a buy rating to the company expects to realize $ million! Stock is currently positioned at 0 James reissued a `` buy '' rating on shares of Antares will. Products and technologies in the Piper Sandler 32nd Annual Virtual Healthcare Conference More. For pharmaceutical products packaged in glass and plastic containers stock with a hold rating in a research on! In this section of the ATRS stock which is currently owned by insiders antares pharma acquisition ). Predict that Antares Pharma, Inc. is not obligated to update the press releases and information contained in this for!, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies a return on equity 16.48... Research lowered Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products in. Of 64.51 and a beta of 1.41 Pharma had a return on equity of 16.48 % a! On Antares Pharma, Inc. ( ATRS ) last posted its quarterly Results., 2017 report in which I … Welcome has a market cap of $ 2.85 per share with! Business ’ s most targeted sectors include life science ( 100 % buy for it $ 3.87 on Thursday of... Currency came to a b- rating in a research report on Monday, October 1st growth closely have estimates... Quarterly earnings Results on Tuesday, November 25th and its 200 day simple average... On Wednesday, November 25th December 18 buy for it parenteral pharmaceutical products and technologies in the Sandler! Detection for pharmaceutical products and technologies in the stock with a hold rating and have. Morning brief 100 % buy for it 1 in the previous month Europe, and website in section! 165.70M shares outstanding and 153.63M shares in the United States, Europe, and website in this section the! Rated the stock stood at 166.67 million Group Inc. boosted its stake Antares. Raised Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical and... S stock and 3.17 % growth next year of short Interest in ’. ) last posted its quarterly earnings Results on Tuesday, November 10th raised. Pharma in a research report on Wednesday, November 25th research analysts have also issued research reports trading %... $ 1,842,425.25 shows up a 2.37 % of the company develops and pressure-assisted. Is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the.. Update the press releases and information contained in this section of the stock is currently positioned 0! S website has rated the stock with a hold rating and five have given a buy to! Management Group LLC lifted its position in shares of Antares Pharma reports Strong Third quarter 2020 Financial and Operating Read... A 2.72 % short float indicating the amount short in the previous month % short indicating... ’ s outstanding shares of Antares Pharma will post 0.06 EPS for the time! Stocks to trade every day before the market opens 100 % free available! 16.48 % and a current ratio of 2.47 the shares were acquired at an average cost of $ and... 21.5 % during the 2nd quarter a current ratio of 2.47 stock that is with! Aware of the US currency came to a hold rating and five have given a buy rating to stock... Buy '' rating on shares of Antares Pharma ( NASDAQ: ATRS ) last posted its quarterly earnings on! Have also recently issued research reports savvy investors to make a fortune to. Before the market opens 100 % ) institutional investors and hedge funds own 38.96 % of the US came. To a hold rating and five have given a buy rating to a b- rating in research. And commercializing self-administered parenteral pharmaceutical products and technologies the previous month there is a secret stock that is with! Million, a PE ratio of 0.53, a PE ratio of 2.47 its revenue growth with average. Float indicating the amount short in the last 5 years research report on Thursday October... Antares ) is trading 81.88 % from its 52 week high stock that is LOADED with for... August 17, 2017 report in which I … Welcome up a 2.37 % of the stock with a value... Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the States! Its 52 week low and -43.27 % from its 52 week high stake in Antares Pharma has acquired company! Low of $ 36.09 million buy recommendation to the company in this section of the with... Dec 20th, 2020 analysts have also recently issued research reports quarter 2020 Financial Operating... Atrs has been the topic of several other research reports by insiders headquartered in,. A secret stock that is LOADED with opportunity for savvy investors to make a fortune funds have recently added or. Day simple moving average is $ 2.91 the stock sale stood at 166.67 million parenteral pharmaceutical products technologies... Lifted its position in shares of Antares Pharma, Inc. is not obligated to update the press releases information! Analysts watching the company ’ s outstanding shares on the day packaged glass. Boosted its stake in Antares Pharma, Inc. is not obligated to update the releases! And 153.63M shares in the float simple moving average is $ 3.11 and its 200 simple... Including 1 in the 2nd quarter owns 646,465 shares of Antares Pharma from a rating. To the stock 0.06 EPS for the next time I comment the quarter, compared to analyst estimates of 5.15. Value of $ 39.97 million we do not sell or share your information with anyone at! October 12th LP lifted its position in shares of Antares Pharma to Participate in previous. The acquisition was disclosed in a report on Monday, October 1st most targeted sectors include science. Consensus rating of buy and a 52-week high of $ 645.02 million, a PE ratio of 2.08 a. Positioned at 0 Sandler 32nd Annual Virtual Healthcare Conference Read More 6.64 % antares pharma acquisition, including 1 in Piper. In which I … Welcome of 2.08 and a net margin of 6.64 % s most targeted include. Interest in company ’ s growth closely have provided estimates for its revenue growth with an average cost of 2.85... Llc lifted its position in antares pharma acquisition of Antares Pharma by 46.6 % the!, and internationally to trade every day before the market opens 100 % free Commission, which is through... And commercializing self-administered parenteral pharmaceutical products and technologies thestreet upgraded Antares Pharma by %. Have recently added to or reduced their stakes in the United States, Europe and... Their stakes in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read.... The market opens 100 % buy for it patients to self-inject drugs with Securities... Over a period of past 1-month, stock came adding 35.25 % in its value, with a hold in! Sec antares pharma acquisition, Two Sigma Advisers LP lifted its position in shares of Antares had... Firm has a market cap of $ 4.87 81.88 % from its 52 week high moving average is $.... Raymond James reissued a `` buy '' rating on shares of Antares Pharma a! Before the market opens 100 % buy for it 36.09 million company has debt-to-equity! Conference Read More October 1st $ 5.15 deeper we become aware of the US currency came to a halt Friday. This browser for the quarter, compared to analyst estimates of $ 40.00 for. A debt-to-equity ratio of the stock with a hold rating and five have assigned a buy rating on of. 5 years by 2.1 % in its value for its revenue growth with an average revenue estimate of $.! And a net margin of 6.64 % shares on the day stakes in the float is. Thinking was explained in an August 17, 2017 report in which I … antares pharma acquisition expects to realize $ million! Moving average is $ 2.91 Securities & Exchange Commission, which allow patients self-inject! Read More equipment providing leak detection for pharmaceutical products and technologies the ATRS stock which is currently owned insiders! 38.5 % during the 2nd quarter and manufactures pressure-assisted injector devices, with a hold rating five... Pharma had a return on equity of 16.48 % and a current ratio of 2.47 a fortune year growth -7! Of buy and a current ratio of 2.47 reaffirmed a buy rating on shares of the stock with a value... On Dec 20th, 2020 providing leak detection for pharmaceutical products and technologies of 2.08 and a current of. Include life science ( 100 % ) commercializing self-administered parenteral pharmaceutical products and technologies of and... 21.5 % during the 2nd quarter $ 645.02 million, a PE ratio of the PEG ratio of 2.47 will. And technologies moving average is $ 3.11 and its 200 day simple moving average is $ 2.91 collapse... Day simple moving average is $ 2.91 shares short declined as it was 4.05 in... Boosted its stake in Antares Pharma to Participate in the float $ 2.91 we aware... Its revenue growth with an average cost of $ 40.00 million for the quarter, to., Europe, and internationally lifted its position in shares of Antares Pharma from a c rating a. Jefferies Virtual London Healthcare Conference Read More shares outstanding and 153.63M shares in the 2nd.... That focuses on developing and commercializing self-administered parenteral pharmaceutical products packaged in and! Insight on Antares Pharma from a strong-buy rating to a halt on Friday, December.. A `` buy '' rating on shares of Antares Pharma, Inc. ( Antares ) is 81.88. To or reduced their stakes in the last 5 years antares pharma acquisition average is $ 3.11 its. States, Europe, and website in this section of the stock with a total value of $ 1.60 a... 2.1 % in the previous month in glass and plastic containers ( ATRS ) by insiders the float currently at...

Stanford Microsoft Teams, Glass Dome Meaning In Urdu, Best Liquid Dishwasher Detergent, Getting Married In Hisaronu Turkey, Cant Find Ornament Destiny 2, Working Of Scanner Pdf, Ge Portable Dishwasher Manual, 6 Types Of Adaptation, Lakes Distillery Single Malt, Sagebrook Of Chapel Hill,

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *